Introduction
Natural background radiation accounts for the greatest radiation exposure of the average member of the UK population (Watson et al 2005) . The largest component of the effective dose from natural background radiation is due to radon, which delivers its dose almost entirely to the respiratory system. This is known to cause lung cancer and an association can be demonstrated in epidemiological studies of exposures in homes (Darby et al 2005 , Krewski et al 2006 , Lubin et al 2004 . Mechanistic assumptions regarding radiation risks are generally interpreted to suggest that there will be a finite risk of cancer induction down to very low doses (UNSCEAR 2000 , ICRP 2007 ). While it is accepted that a linear non-threshold (LNT) dose-response relationship is unlikely to apply to all radiation exposures and cancer types (UNSCEAR 2000, Harrison and Muirhead 2003) , it is judged that this is an appropriate assumption for radiation protection purposes (ICRP 1991 , Wall et al 2006 .
Ionising radiation is one of the few known causes of childhood cancer and the fact that the effects of radon exposure can be detected by epidemiology generates interest in a possible link between natural background radiation and childhood cancer, in particular leukaemia. It is reasonable to assume that leukaemia is initiated as a result of mutations occurring in haemopoietic stem cells, located primarily in the red bone marrow (RBM) within the skeleton (UNSCEAR 2000 , ICRP 2007 . The development of haemopoiesis in utero is complex, but again it is considered that dose to RBM in the developing foetal skeleton may be the best indicator of leukaemogenic risk (Harrison 2009) . In this paper, we consider the dose to RBM from different sources of natural background radiation with the aim of improving our understanding of the role that natural radiation exposures may play in the causation of childhood cancer and the extent to which this can be investigated by epidemiology.
While exposures to penetrating external radiation result in fairly uniform dose distribution throughout the body, internal emitters in many cases are retained within specific organs and tissues and may also continue to deliver dose over periods of years (ICRP 1991 , Harrison and Day 2008 . In considering doses from alpha-emitting nuclides, account must also be taken of the greater effectiveness of alpha particles compared to photons and electrons in causing cancer.
The International Commission on Radiological Protection (ICRP) devised a scheme for protection purposes that enables doses from different sources and different radionuclides to be summed in a single risk-related quantity, effective dose, used in the control of stochastic risks (cancer and hereditary effects). This was originally introduced in ICRP Publication 26 (ICRP 1977) , though the name was introduced later (ICRP 1978 (ICRP , 1984 . Weighting factors have changed somewhat, but essentially the same quantity has been recommended in more recent publications (ICRP 1991 (ICRP , 2007 . Absorbed doses (Gy) to organs and tissues are multiplied by radiation weighting factors (20 for alpha particles compared to 1 for photons and electrons) to give equivalent dose (Sv). Equivalent doses are then summed, multiplying by tissue weighting factors to take account of differences between organs and tissues in their radiosensitivity and contribution to total detriment from cancer and hereditary effects. The dose coefficients (Sv Bq −1 ) published by ICRP (1998) for internal emitters are committed effective doses per unit radionuclide intake, based on estimates of dose integrated to 70 years of age.
Effective dose was introduced to provide a metric for limiting the stochastic risk to the body as a whole. It is important to recognise that the quantity involves a number of simplifications, particularly in radiation and tissue weighting factors, that are not appropriate when attempting to assess doses and cancer risks to individuals or to specific population groups. Nevertheless, the concept has proved of general utility and is very widely used as a yardstick of the magnitude of radiation exposures. For example, it is the quantity in which both national and international reviews of radiation exposure are normally reported (e.g. Watson et al 2005 , UNSCEAR 2000 . It is also the quantity in which the results of radiation surveys are generally given (e.g. Wrixon et al 1988) . In this paper, we estimate some components of RBM dose from published values of effective dose.
The radiation exposure of the UK population, in terms of effective dose, from all sources of radiation has been regularly reviewed by the Radiation Protection Division of the Health (This figure is in colour only in the electronic version)
Protection Agency (HPA) and by the National Radiological Protection Board, its predecessor organisation. The most recent review was by Watson et al (2005) . The main components of the effective dose are summarised as a pie chart in figure 1. The sources of natural radiation exposure can broadly be divided into three components:
(1) Penetrating radiation from cosmic rays and terrestrial gamma rays.
(2) Radionuclides in food and drink.
(3) Isotopes of radon and their decay products.
Exposures which deliver the same effective dose may involve quite different patterns of organ dose. For many components of natural radiation, doses across the body are reasonably constant and all organs receive similar doses. However, particularly in the case of internal emitters, organ doses can differ widely. In this paper we concentrate our attention on doses to RBM, developing a discussion of doses to a typical member of the UK population . In evaluating age dependent doses, it is common to consider doses due to exposures at three ages, infants aged 1 year, children aged 10 years and adults (e.g. ICRP 2005 , Watson et al 2005 , Kendall and Smith 2005 . However, detailed investigations of risk will ideally use more detailed modelling of the age dependence of doses. In this paper, we consider in utero and early postnatal doses as well as exposures at the ages of 1, 5, 10 and 15 years. Comparisons are made with doses to adults. We first consider the various components of the committed equivalent dose to the RBM for exposures at the ages of 1, 5, 10 and 15 years and as adults. This provides a general overview of the contributions to RBM dose. However, if the radiological consequences of radiation exposures are to be assessed in detail then the protraction of doses in time must be taken into account. In more detailed assessments it is also desirable to consider the dose to the embryo and foetus and the dose to a breast-fed infant. We therefore assess these doses for a typical UK child, estimating doses received in utero and annually throughout childhood to age 15 years. Finally we consider the different contributions from high and low linear energy transfer (LET) radiation. In the tables of results, individual contributions are shown in sufficient detail that specific contributions can be modified to assess doses for different exposure patterns if required.
2.
Committed equivalent doses to RBM of adults, children and infants from the components of natural background radiation 2.1. RBM doses from radionuclides in food and drink Kendall et al (2006) reviewed doses from ingestion and inhalation of radionuclides in food and drink. With the exception of the contribution from radioisotopes of radon, doses due to inhalation are two orders of magnitude lower than those due to ingestion and have been disregarded in what follows. In this paper committed RBM doses were calculated using ICRP (1998) dose coefficients applied to 1 year's ingestion of radionuclides in food at the five ages: 1, 5, 10 and 15 years and adult. Watson et al (2005) gave data on intakes of radionuclides in food at ages of 1 and 10 years and for adults. In the present assessment, intakes for 15-year-olds were obtained from data published by Smith and Jones (2003) . In the absence of published data for 5-year-olds, estimates were made on a nuclide by nuclide basis by scaling the intakes for a 10-year-old according to the relative energy requirements at the two ages (ICRP 2002) .
Concentrations of potassium-40 and rubidium-87 within the body are controlled homeostatically and doses from these nuclides cannot be estimated from intakes and dose coefficients. Watson et al (2005) discussed the age variation in effective doses from 40 K. Following UNSCEAR (2000), a somewhat higher dose was ascribed to the 10-year-old child than to the 1-year-old infant or the adult. This is a consequence of the relative concentrations of potassium in the body at the different ages (ICRP 1975) which is highest around the age of 10 years, though the variation with age is small (about 12%). We have adopted this age variation and have assigned the same dose at 15 years as that to the adult and, following the variation in the concentration of body potassium, taken the dose at 5 years to be the mean of that to the 1-year-old and that to the 10-year-old. Account has also been taken of observations that RBM has a lower concentration of potassium than do many other body tissues and so the dose to the RBM from 40 K is about 80% of the effective dose at all ages (ICRP 1998). There is little information on the age dependence of RBM dose from 87 Rb, but the contribution from this radionuclide is small. Watson et al (2005) assigned an effective dose from 87 Rb of 2 µSv year −1 at all ages. RBM doses are somewhat higher than the effective dose (ICRP 1998 , Simmonds et al 1995 and we have used a value of 3 µSv year −1 at all ages. Details of intakes of radionuclides and the resulting committed RBM doses are given in tables 1 and 2, respectively. The estimated total committed equivalent doses from annual ingestion of radionuclides in food are greatest at 1 year of age at about 600 µSv, falling to about 340 µSv for adults. At all ages, doses are dominated by contributions from 40 K, 210 Pb, 210 Po and 228 Ra. For each except 40 K, the majority of the dose is due to alpha particle emissions, from 210 Po after intakes of 210 Pb and 210 Po, and from a series of alpha-emitting progeny of 228 Ra (see section 4). The relative contributions that the different radionuclides make to the RBM dose are broadly similar at all five ages.
RBM doses from isotopes of radon and their decay products
Inhalation of the two isotopes of the natural radioactive gas radon, 222 Rn and 220 Rn, often referred to as radon and thoron, respectively, results in delivery of dose predominantly to the respiratory tract. Most of this dose is due to the decay products rather than to the gas itself. For both isotopes, doses to other organs and tissues are very much smaller. Doses from 222 Rn and its progeny can be calculated in two ways: the so-called 'epidemiological' and 'dosimetric' approaches. ICRP (1993a) has adopted the epidemiological approach, using the 'dose conversion convention' in which the lung cancer detriment per unit radon exposure is compared with the total detriment associated with unit effective dose, estimated largely on the basis of studies of survivors of the Japanese atomic bombings (ICRP 1993a) . Alternatively, various dosimetric models of the human respiratory tract, including the ICRP (1994) model, can be used to estimate equivalent dose to the lungs and effective dose per unit radon exposure (Marsh et al 2005) . To estimate RBM doses, it is necessary to model the biokinetics of the behaviour of radon isotopes and their progeny, including their uptake from the lung to blood and subsequent skeletal retention.
An important parameter in calculating doses from radon decay products is the rate of uptake of material from the respiratory tract to body fluids. The ICRP (1994) model specified three default absorption rates as Type F (fast), Type M (moderate) and Types S (slow). Smith (2002, 2005) presented doses for Type F and Type M behaviour of 222 Rn decay products. The absorption rates correspond to half-times of retention of 10 min (100%) for Type F and 100 min (10%) and 140 days (90%) for Type M. There is some evidence that the lead decay product of 220 Rn is lost from the lung with a 10 h half-time (Marsh and Birchall 1999) , more slowly than Type F kinetics and similar to Type M kinetics.
While the dose to the respiratory tract is dominated by decay products, 222 Rn gas makes a larger contribution than the decay products to the doses to other organs and tissues, particularly those with a relatively high fat content, including RBM. Kendall and Smith (2002) estimated the mean annual RBM dose for an adult from 222 Rn gas in the home as about 65 µSv. The contribution from the decay products was estimated as 28 or 3 µSv depending on whether they are assumed to exhibit Type F or Type M behaviour. In this paper we have adopted Type F kinetics which imply dose coefficients that agree more closely with lung cancer risks derived from epidemiology (Kendall and Smith 2002) .
Estimates of RBM doses from 222 Rn and its decay products have been published for the ages of 1 year, 10 years and adults and it is necessary to estimate the doses at 5 and 15 years. However, the variation with age is not large, doses being around 10% higher for the 10-year-old than at 1 year or for adults. Adults and young children spend around 90% of their time indoors; for children aged 5-10 years the figure is about 80% (Smith and Jones 2003) . When allowance for these factors is made, the variation of 222 Rn dose with age is negligible and is estimated as a total of about 80 µSv year −1 at all ages. Radon-220 has been estimated to contribute about 0.1 mSv year −1 to the effective dose to the average UK citizen (Watson et al 2005) . This is a small part of the total effective dose from 220 Rn and 222 Rn combined. Doses to organs and tissues from 220 Rn decay products were discussed by Kendall and Phipps (2007) . Most of the dose from thoron and decay products comes from the 212 Pb decay product. The UK mean equilibrium equivalent 220 Rn concentration has been estimated to be 0.3 Bq m −3 (Wrixon et al 1988 , Proctor 2006 ) and mean annual RBM doses for 1-year-olds, 10-year-olds and adults were calculated using estimates of annual intakes of air given by Watson et al (2005) . Doses are smaller than those from 222 Rn, but there is more evidence for variation with age, with estimates of around 10 µSv year −1 for adults, doubling to around 20 µSv year −1 at 1 year of age (table 2) . In this paper, doses for 15-year-olds were taken to be the same as those to adults and doses to 5-year-olds were taken as intermediate between those for the 1-and 10-year-olds.
Gamma rays and cosmic rays
Both cosmic rays and gamma rays from terrestrial sources are very penetrating and doses vary relatively little among body organs and tissues. Saito et al (1990) calculated the pattern of doses delivered by terrestrial gamma rays. They concluded that, for an adult, the RBM dose is 93% of effective dose. Petoussi et al (1991) presented calculations which relate the organ doses from natural gamma radiation to an 8-week-old baby and a 7-year-old child to the effective dose to an adult. For red bone marrow, the factors are 1.24 and 1.12, respectively. The variation of RBM dose with age is complex: the distribution of RBM in the skeleton varies with age as does the degree of shielding provided by the rest of the body. Precise estimates of RBM doses at intermediate ages must await detailed calculations of photon transport in realistic age dependent voxel phantoms. However, the variation with age is relatively small and, on the assumption that variation is monotonic, we consider that a more realistic picture of RBM dose as a function of age is obtained by interpolation rather than by applying the published values in a crude stepwise manner. The interpolated values shown in table 2 were obtained by considering the variation of RBM dose against the cube root of body mass. The latter is a rough estimate of the linear dimension of the body and is found empirically to vary smoothly with dose. We further assume that similar relationships apply to cosmic rays as to terrestrial gamma rays.
Summary of committed equivalent doses to RBM from natural radiation sources for exposures at different ages
The results shown in table 2 are equivalent RBM doses for annual exposures at different ages, including the annual equivalent dose from external radiation plus the committed equivalent dose from radionuclide intakes in the year. The estimated total RBM doses from all natural sources of radiation are greatest for the 1-year-old at about 1500 µSv, with progressively smaller values for older children, falling to a value of about 1100 µSv for an adult. There is a much greater variation with age in the contribution from radionuclides in food than in the contribution from the external sources of radiation (gamma and cosmic rays). Radionuclides in food make the largest contribution to the overall dose and gamma rays from terrestrial sources and cosmic rays make a much larger contribution than do isotopes of radon (with their decay products).
The committed equivalent dose estimates in table 2 can be compared with an earlier assessment of doses to the Cumbrian population (Simmonds et al 1995) . This was concerned with doses from anthropogenic radiation but also gave red bone marrow doses from natural radiation for a 10-year-old child. The estimated RBM equivalent dose from annual exposure was given by Simmonds et al (1995) as a little less than 1200 µSv compared with the value of 1350 µSv in table 2. Part of the difference arises because the mean gamma ray dose rate in Cumbria is only three-quarters of the national average. Estimates of cosmic ray doses have increased somewhat because the neutron component at sea level was re-assessed from about 20 to about 70 µSv year −1 in the 1990s (UNSCEAR 2000 , Hughes 1999 ) and the contribution from air travel has gone up from 10 to 30 µSv year −1 . In this work we have also taken the dose from these types of radiation to be a little higher for a 10-year-old than for an adult, while Simmonds et al (1995) assumed them to be the same. The two estimates of the total committed equivalent dose from food and drink are very similar, though the relative contributions from different nuclides have changed. The annual RBM dose due to inhalation of 222 Rn estimated by Simmonds et al (1995) was similar to that in table 2 while our estimate of the RBM dose due to 220 Rn inhalation is about 2.5 times lower.
Equivalent doses to RBM received in utero and annually during childhood to the age of 15 years
For analyses of risks of radiation exposure in childhood, it is necessary to determine the time-course of dose delivery and estimate annual received doses. The components of natural radiation listed in table 2 consist of the external sources, cosmic rays and terrestrial gamma rays, and internal sources. Internal exposures result from inhalation of Rn isotopes and ingestion of radionuclides in food and drink. The external sources of natural radiation give instantaneous doses and the calculation of annual doses is not complicated by dose protraction. The decay products of 220 Rn and 222 Rn which are of dosimetric importance have physical half-lives of a few hours or less. There is therefore no requirement to consider dose protraction following Rn inhalation. However, dose protraction must be considered for ingested radionuclides, with intakes in a given year giving rise to dose in that year and, depending on the radionuclide, also to doses in subsequent years. The degree of dose protraction will depend on the physical half-life of radionuclides and their decay products, and also on the rates at which it is lost from the organs and tissues of the body by biological processes. Doses will also decrease with time as organs increase in mass and radionuclide concentrations decrease. For a complete analysis of doses received during childhood, it is necessary to consider in utero doses, including doses from the placental transfer of radionuclides. It is also necessary to consider doses received in the immediate postnatal period, including contributions from radionuclides transferred to the newborn child in breast-milk.
RBM doses in utero
In utero development is generally considered as consisting of the embryonic period, up to 8 weeks from conception, and the foetal period, continuing to parturition at 38 weeks (ICRP 2001) . Terrestrial gamma rays and cosmic rays are penetrating external radiations that can be expected to deliver reasonably uniform doses to the developing embryo and foetus as well as to maternal organs. Saito et al (1990) calculated doses to various organs from the three important components of terrestrial gamma rays (photons from nuclides from the 238 U series, the 232 Th series and from 40 K). Dose to the uterus from all three types of photon is very close to 90% of the adult effective dose. This will be a good estimate of the dose to the embryo and we take this factor to apply as an approximation for doses to the foetus from terrestrial gamma rays. We also apply it to cosmic rays. However, the maternal doses must be reduced by a factor of 0.75 because doses to the embryo/foetus are incurred in the 9 months of pregnancy, not over a whole year.
For 222 Rn and decay products, we use the estimates of in utero doses given by Kendall and Smith (2002) . These amount to about 10 µSv if the decay products are taken to have Type F kinetics. Kendall and Phipps (2007) reviewed doses from 220 Rn and decay products. They did not give estimates of in utero doses, but results in the paper indicate that doses from 220 Rn gas are very much smaller than those from the decay products and that, of the decay products, 212 Pb dominates 212 Bi. ICRP (2001) has not given in utero dose coefficients for intakes of 212 Pb by the mother. However, calculations using the PLEIADES code give a RBM dose coefficient for the foetus of 3.14 × 10 −7 Sv Bq −1 inhaled by the mother. This implies a dose to the RBM of the foetus during pregnancy of about 2 µSv, with a dose two orders of magnitude smaller in the first year of life.
Doses to the embryo/foetus from other radionuclides transferred across the placenta are less straightforward to estimate. The mother's body will contain radionuclides, reflecting the balance between intakes, decay and excretion over her lifetime. A proportion of each of the radionuclides present in her body during pregnancy will be transferred to the embryo/foetus and a proportion of the activities transferred will still be present when the child is born. Doses to the embryo and foetus from radionuclides transferred from the mother's body are discussed in detail by ICRP (2001) with results for a further four nuclides given in a later report (ICRP 2004) . Special calculations were undertaken, using the ICRP (2001, 2004 ) models as implemented in the PLEIADES code , to estimate in utero RBM doses resulting from intakes of radionuclides by the mother. ICRP (2001, 2004) does not give dose coefficients for 87 Rb, nor is a specific model recommended. However, the biokinetics of rubidium are similar to those of potassium. The much smaller doses from 87 Rb were estimated on the basis of doses from 40 K. Equivalent doses to the embryo/foetus from radionuclides transferred across the placenta are summarised in table 3. These assume continuous intakes by the mother from birth to age Table 3 . Annual equivalent doses (doses received in the year indicated, not committed doses as in table 2 (see text)) to the red bone marrow (RBM) of offspring in utero and by year after birth considering transfer of radionuclides in utero and in breast-milk following maternal intake of naturally occurring radionuclides throughout her life. (Note: inhalation of radon isotopes and progeny and ingestion of other radionuclides in food, continuing from birth of the mother, throughout pregnancy (9 months) beginning at age 25 years, and 6 months' breast-feeding. Doses for years 11-12 and later are zero to the precision of this table. Doses contributed by isotopes of uranium and thorium are small and are not shown separately but their contributions are included in the totals.) RBM dose to offspring (µSv), in period (year)
Radionuclide In utero 0-1 1-2 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10 10-11
In utero transfer after intake by mother from birth 25 and throughout pregnancy. According to these estimates, almost half the dose comes from 210 Pb with the next largest contribution, about 30%, from 40 K. About 60% of the total dose is incurred in utero, but a significant part of the dose will be incurred after the child has been born: about a quarter in the first year of life and approaching 15% in later years.
RBM doses in the first year of life
Doses to the newborn infant from external radiation and from inhalation of 220 Rn and 222 Rn will be very similar to those to the reference infant aged 1 year considered above (section 2). However, doses from ingested radionuclides will differ substantially because intakes in the early part of the year will be largely confined to radionuclides in breast-milk and because absorption to blood from the immature intestine of the suckling infant is generally greater than after weaning (ICRP 2004) .
RBM doses from ingestion of radionuclides in breast-milk were calculated for a period of 6 months after birth using ICRP models implemented using the PLEIADES code . As in the calculation of in utero doses, it was assumed that the mother's intake of radionuclides had continued throughout life, with pregnancy occurring at 25 years of age. The results in table 3 show that almost three-quarters of the estimated total equivalent dose is contributed by 40 K, with 210 Pb and 210 Po accounting for a further 14% of the total. Over 90% of the dose is delivered in the first year of life, but 210 Pb and 228 Ra and their progeny deliver a significant part of their dose in later years.
Doses from radionuclides in solid foods consumed in the second half of the first year of life after weaning were calculated assuming half the annual intake for a 1-year-old. It is notable that the total dose from solid food in the first year of life is almost as large as that incurred in the second year of life, despite the intakes of radionuclides being only half as large. This is a consequence of higher intestinal absorption of radionuclides during the first year of life. For example, the gut uptake factors for ingestion by an infant aged 3 months of the radiologically important elements polonium and radium are twice the values at 1 year and doses are calculated assuming a linear reduction in absorption between 3 months and 1 year (see discussion).
RBM doses from radionuclides in food
Calculations of annual RBM doses from ingestion of radionuclides over the age range 1-15 years were carried out using the PLEIADES code with the most recent ICRP biokinetic and dosimetric models (ICRP 1996) . Data on intakes of radionuclides by single year of age are not available and the intakes shown in table 1 were assigned to other years as indicated in the footnote to table 4. As for doses resulting from placental transfer to the foetus and transfer in breast-milk, significant dose protraction is evident in the cases of 210 Pb and 228 Ra. Since the data in table 4 are for continuing annual intake of radionuclides, the protraction of dose results in increasing annual received doses over a number of years, particularly for 228 Ra. The largest contribution to total RBM dose comes from 210 Po and the contributions from 40 K, 210 Pb, 210 Po and 228 Ra account for approaching 95% of the total.
High and low LET components of RBM dose
As noted in section 1, the equivalent doses considered above combine contributions from radiations with low and high LET. The external radiation sources are largely low LET radiation, with a radiation weighting factor of 1, while the dose delivered by alpha particles from radionuclides is high LET, with a radiation weighting factor of 20 (ICRP 1991 (ICRP , 2007 . For scientific applications, including epidemiological analyses, absorbed doses (Gy) should be calculated, considering low and high LET components separately. ICRP radiation weighting factors are intended for protection purposes only, with simplifications that neglect recognised differences in, for example, the effectiveness of different low LET radiations and differences in the effectiveness of alpha particles for different cancer types. In particular, for the induction of leukaemia in adults there is evidence that, in terms of absorbed dose, alpha particles are only a little more effective than low LET radiation (ICRP 2003 , Harrison and Muirhead 2003 . Doses from 14 C, 40 K and 87 Rb emit exclusively low LET radiations; 210 Po gives high LET doses which are many orders of magnitude larger than the corresponding low LET contributions. The other radionuclides considered here give both high and low LET doses, though the former are generally larger. Gamma rays and the directly ionising component of cosmic rays are of low LET. However, about a quarter of the equivalent dose at sea level from cosmic rays is from neutrons. The radiation weighting factor for neutrons depends on their energy, but they are assigned to the high LET rather than the low LET fraction.
The results in tables 5 and 6 show that the low LET component of RBM dose from radionuclides in food (both before and after weaning) and from radionuclides transferred across (2005) to other ages as follows: 1 year applied to 1 year and 2 year; 5 year to 3-7 years; 10 year to 8-12 years and 15 year to 13-15 years. This differs somewhat from the assumptions of Simmonds et al (1995) where 1-year-old intakes were applied to 1-3 years; 5 year to 4-8 years; 10 year to 9-14 years.) RBM dose (µSv), from radionuclide a Dose in year to age (year) 14 a Doses contributed by isotopes of uranium and thorium are small and are not shown separately but their contributions are included in the totals. b For 6 months' intake in the second half of the year, following 6 months' breast-feeding.
the placenta is typically several times the high LET component. However, because of the high radiation weighting factor for the latter, it makes a larger contribution to equivalent dose. The low LET component of dose from external radiation sources dominates the high LET component. When all sources are considered together, the low LET absorbed dose is typically a factor of 30 or so larger than the high LET dose. Table 7 summarises RBM doses by broad source of natural radiation exposure, from doses received in utero by single years of age up to 15 years of age, giving annual received doses (not committed doses). There is relatively little variation in the annual totals from the second year of life to 15 years of age with a slow decrease in dose as age increases. Doses in the first year of life are somewhat higher than in subsequent years, largely because of increased intestinal absorption of certain radionuclides (see below). Simmonds et al (1995) also gave year by year summaries of RBM doses from natural radiation (see their appendix E). These are broadly similar to the results presented here with one exception. Simmonds et al (1995) reports that the high LET component of dose from natural radiation in the first year of life is four or five times larger than that in later years; this results in the total equivalent dose from high and low LET radiation combined being about two and a half-times larger in the first year of life than in later years. In the present work, the high LET component of dose in the first year of life is about 20% higher than in later years. For their year by year assessments of dose Simmonds et al (1995) were higher than those used in this assessment, particularly at age 1 year. Moreover, it is likely that the annual intakes received by the various cohorts were assumed to be acute and delivered at the beginning of the year of intake. This would exaggerate the effect of elevated intestinal absorption in the early months of life. In addition, the assessment of Simmonds et al (1995) pre-dates the publication of ICRP (2001, 2004 ) models for the assessment of doses in utero and in the first year of life, and the approaches adopted would have been less firmly based. The main contributors to total annual equivalent doses to the RBM of children are external exposures to gamma and cosmic rays and internal exposures resulting from radionuclides in food (table 7) . Uncertainties in dose estimates are greater for the internal emitters because of the assumptions made in biokinetic models and because a significant proportion of the dose is due to alpha particle emissions for which the calculation of doses to RBM is problematical (ICRP 2007 , Harrison and Day 2008 , Harrison 2009 ). While the doses reported in this paper can be regarded as more reliable than the earlier assessment of Simmonds et al (1995) , the model assumption of increased intestinal absorption in the first year of life declining linearly to the end of the year is likely to be conservative. Although judgements are reliant on animal data, it appears that increased absorption will be confined to the period of breast-feeding and may not apply to radionuclide absorption from foods later in the first year (Harrison and Fritsch 1992, ICRP 2004) . The biokinetics of 210 Pb and 210 Po are complex, particularly in terms of the deposition and retention in skeletal tissues (ICRP 1993b . While 210 Po deposits in red bone marrow, 210 Pb (as well as isotopes of Ra, Th and U) deposit in mineral bone and the extent of alpha particle irradiation of RBM is difficult to assess. The behaviour of 210 Po ingrown from ingested 210 Pb was taken to be that specified in the current ICRP models (ICRP 1993b ). An additional complication is that dosimetric models currently consider average doses to RBM and do not take account of peripheral alpha particle irradiation from radionuclides deposited in bone and the location of different populations of haemopoietic stem cells within the Table 6 . Low and high LET components of annual absorbed doses (doses received in the year indicated, not committed doses as in table 2 (see text)) to red bone marrow of offspring in utero and by year after birth considering transfer of radionuclides in utero and in breast-milk following maternal intake of naturally occurring radionuclides throughout her life (ingestion of radionuclides in food from birth of the mother, throughout pregnancy (9 months) beginning at age 25 years, and 6 months' breast-feeding), inhalation of radon isotopes and exposure to cosmic rays. marrow (Harrison 2009 ). Even more complex is the calculation of in utero haemopoietic doses, since it is well established that there are multiple and changing sites of haemopoiesis during early development before the RBM becomes established as the predominant site (Shagina et al 2007) . Nevertheless, the contribution to equivalent dose from low LET radiation is larger than that from high LET and this will reduce uncertainties in the total equivalent dose to RBM. Calculations based on standard risk models have been carried out to investigate the proportion of childhood leukaemia cases caused by exposure to natural radiation (Wakeford et al 2009) . The fraction depends on the model used to transfer risk factors to the UK population, but might be about 20%, in agreement with earlier estimates (Wakeford 2004 ). Nevertheless, a large case-control study in the UK failed to find an association between childhood leukaemia and exposure to natural radiation sources (UKCCS Investigators 2002a , 2002b ) and a degree of caution has been advocated in accepting the reality of a risk of this size (Greaves 2006) . However, the likelihood of an epidemiological study being able to detect the effects of natural radiation exposures depends both on the magnitude of the doses and on the variation of doses between individuals (for case-control studies) or between areas (for geographical correlation studies). A general survey of the variation in exposures from gamma rays and from radon in the UK has been published . It is intended to build on the calculations presented here to explore the role of natural radiation as a cause of childhood leukaemia and the prospects for epidemiological studies on this question.
Summary and discussion

